TABLE 2.
Type of treatment | No. of patients (%) |
---|---|
1st line treatment | |
Concurrent chemoradiotherapy | 1598 (13.0) |
Sequential chemoradiotherapy | 200 (1.6) |
Thoracic radiotherapy | 782 (6.3) |
Chemotherapy | 6736 (54.7) |
Palliative care | 2993 (24.3) |
Others | 11 (0.1) |
Total | 12 320 (100.0) |
Chief treatment through all lines | |
Concurrent chemoradiotherapy | 1689 (13.7) |
Sequential chemoradiotherapy | 221 (1.8) |
Thoracic radiotherapy | 662 (5.4) |
Chemotherapy | 7790 (63.2) |
NSCLC use of EGFR‐TKIs yes | 2053 (26.4) a |
NSCLC use of EGFR‐TKIs no | 4105 (52.6) a |
SCLC use of EGFR‐TKIs no | 1613 (20.7) a |
SCLC use of EGFR‐TKIs yes | 6 |
Histology unknown | 13 |
Palliative care alone | 1952 (15.8) |
Others | 6 (0.1) |
Total | 12 320 (100.0) |
Abbreviations: EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer.
The percentage among patients treated with chemotherapy alone.